Enumeral Biomedical Holdings Inc
Enumeral Biomedical — Technical Presentation (July 2015)
39 slides from Enumeral Biomedical's technical presentation, Jul 28, 2015
Slide 1: Enumeral Drug Discovery & Development: July 2015 Program Updates
Enumeral Drug Discovery & Development July 2015 Program Updates
Slide 2: Overview
2 Overview • Program Overview • PD - 1 • TIM - 3 • TCR recovery (single cell) 2
Slide 3: Program Overview
Program Overview
Slide 4: Improving anti-tumor effects of IMR-targeted antibodies
4 Improving anti - tumor effects of IMR - targeted antibodies 4 Tumor cells Stromal cells Homing Suppression Tolerance Tumor reactive T cells traffic to the tumor Inhibitory signals inhibit effector function Immune system may be tolerized or suppressed Leverage high - dimensional functional analysis
Slide 5: Single cell analysis of immune effector cell function: profiling rare cell types
Single cell analysis of immune effector cell function: profiling rare cell types 5 Chattopadhyay et al 2014 High - dimensional functional analysis at single cell level enable assessment of rare cellular subsets within patient - derived biopsy: patient - centric paradigm for drug selection and combin
Slide 6: Enumeral approach: integrated single cell functional immune profiling
Enumeral approach: integrated single cell functional immune profiling for drug discovery and development 6 After Tsioris et al 2015 function phenotype genomics Patient biopsy + Diverse antibody candidates High - dimensional functional analysis guides antibody selection and further development Divers
Slide 7: Enumeral's Broadly Enabling Platform
7 Enumeral’s B roadly E nabling P latform 7 84,672 microwells • High - density bio - chip and one - day process • Measures key parameters of function of individual immune cells from patient samples • Uniquely enumerates and rapidly identifies rare immune cells critical to responses • Validates targe
Slide 8: ENUM003: PD-1
ENUM003: PD - 1 8
Slide 9: Background: screening design
9 Background: screening design • Two strains of mice were immunized with PD - 1 protein with multiple types of adjuvant • Serum titres were extremely high • Prior to screening, B cell activation was assessed (BLIMP1+) • Screening was performed using primary B cells, specifically screening secreted a
Slide 10: Enumeral platform used for antibody discovery
10 Enumeral platform used for antibody discovery • Mice were immunized with PD - 1 - His • Splenocytes activated with LPS for 3 days • Each screen: 8 devices loaded and screened for IgG, h - Fc (PD - 1), and IgM using Enumeral platform 10 Glass slide Anti - mouse IgG antibody (coated on slide) ant
Slide 11: Raw Hit Rate/Lead Discovery
11 Raw Hit Rate/Lead Discovery • >500 IgG+ PD - 1+ raw screening hits • On average: – Recovery rate of 57.6% matched pairs per screen – 84.2% of those matched pairs showed binding to rhPD - 1 11
Slide 12: Sample pick (detection of secreted antibody)
12 Sample pick (detection of secreted antibody) • Both screens looked for ENUM - 003/IgG hits, screen 2 included an IgM channel to confirm the IgG signal was specific • The IgM antibody helps profile the overall response, but not necessary for identifying 003/IgG hits • Example of raw data from a PD
Slide 13: Hit recovery for hit validation
Hit recovery for hit validation 13 Bioinformatics (Sequencing / Primers) Recovery of VH and VL genes by RT - PCR Topo - cloning and purification of VH and VL PCR products Confirmation of binding to target (ELISA) Day 3 Day 8 Day 10 Day 18 - Cloning into vectors containing constant domains - Co - tra
Slide 14: Diversity and sequence analysis of anti-PD1 hits
14 Diversity and sequence analysis of anti - PD1 hits 14 Screen 1 - 12 Heavy chain AA sequences from PD1 N= 159 sequences shown; 28 families of antibodies OPDIVO® KEYTRUDA® Pidilizumab 26 anti - PD - 1 mAbs confirmed binding to rhPD - 1 after cloning/expression 6 antibodies from different clades cho
Slide 15: Hit confirmation
15 Hit confirmation • n=26 clones were transiently transfected and cultured supernatants were used for hit confirmation testing • Binding confirmation assays: – ELISA: recombinant human PD1 and cynomolgus PD1 – HEK293 - PD1 cells – Primary T cells 15
Slide 16: Enumeral mAb candidate binding to cell-surface expressed PD-1 (HEK293)
16 Enumeral mAb candidate Binding to cell - surface expressed PD - 1 (HEK293) 100244_C7VH10_C8VK5 ++ 100244_C7VH10_C8VK5m1 ++ 100244_C8VH3_C8VK5 ++ 100244_C8VH3_C8VK5m1 ++ 100246_F7VH3_F7VK2 ++ 100258_C1VH4_C1VK1 + 100258_F6VH4_F6VK1 ++ 100258_F6VH4_F6VKm1 ++ 100392_C4VH5_C4VK8 +++ 100394_D5VH9_D5VK
Slide 17: Scale-up of lead clones
17 Scale - up of lead clones • n=6 lead clones were selected for further characterization • ELISA, EC50 determination • SPR, biophysical determination • Binding to cells, EC50 (MFI) • Mapping epitope, using scanning overlapping peptides • Cross - competition, compared to known antibodies 17
Slide 18: Binding Affinity: ENUM mAbs vs. Keytruda mAb
18 Binding Affinity: ENUM mAbs vs. Keytruda mAb EC 50 Keytruda 0.066 ENUM - A10 0.020 ENUM - C8 0.005 ENUM - D4 0.003 ENUM - E1 0.013 ENUM - D2 0.005 18 0 0.5 1 1.5 2 2.5 3 3.5 OD (450nm) Antibody concentration ( μ g/mL)
Slide 19: Binding to cynomolgus PD-1
19 Binding to cynomolgus PD - 1 19 Antibody Concentration ( m g/ml) OD (450nm) 0 0.5 1 1.5 2 2.5 3 3.5 388D4 413E1 413D2 PD1 biolegend • Assay for binding to cynomolgous PD1 • All ENUM lead clones bind to non - human primate (NHP) PD1 • Confirmatory testing for binding to cellular NHP PD1 in progres
Slide 20: Functional Characterization
20 Functional Characterization • Cell based assays for readout on PD1 enhancement of T cell function (proliferation, effector cell function) • PBMCs with exogenous rhPD - L1 - Ig • PBMCs with suboptimal stimulation conditions • PBMC - based MLR reaction • PBMC - based antigen recall (CMV or EBV) 20
Slide 21: Enumeral Antibodies: Superior Function
21 Enumeral Antibodies: Superior Function 21 IFNg secretion (relative to control) N = 5 repetitions for each candidate/condition • PBMC - based assay to determine mAb’s ability to disrupt functional suppression from PDL1 • ENUM candidates compared with : – Control ( stim /no PDL1) – PDL1 (suppress r
Slide 22: Cellular response assays: single cell effector function
22 Cellular response assays: single cell effector function 0 5 10 15 20 25 30 35 40 Isotype Pembro D4 A10 C8 IFN - ϒ Only TNF - α Only IFN - ϒ+ TNF - α Analysis conducted loading 120,000 live cells per device #events 22 Bind to PD - 1 in a manner different from that of currently marketed anti - PD1
Slide 23: Humanization: informatics driven
Humanization: informatics driven 23
Slide 24: Iterative humanization checked by affinity
24 Iterative humanization checked by affinity 24 IGHV1 - 46 IGHV1 - 46 IGHV1 - 3
Slide 25: Humanization
25 Humanization • n =4 clones selected for humanization – Humanization of 388D4 completed • In progress: – Binding: confirm binding and affinity – Specificity: confirm on - mechanism binding – Affinity: assessment compared to clinical standards – Safety: specificity against normal tissue panels 25
Slide 26: ENUM005: TIM-3
ENUM005: TIM - 3 26
Slide 27: TIM-3 updates
27 TIM - 3 updates • 3 screens were processed (one BL6 and two NZB) • 169 cells were picked for RT - PCR • 88 matched pairs were recovered representing 30 unique antibodies • 8 reformatted antibodies were showed to bind rhTIM - 3 • 41 other antibodies are undergoing cloning/expression • More screens
Slide 28: Anti-TIM-3 mAbs: Binding confirmation
28 Anti - TIM - 3 mAbs : Binding confirmation 28 Binding confirmation performed with with rhTIM - 3 - his IgG expression TIM - 3 binding
Slide 29: TIM3 screening hit diversity
29 TIM3 screening hit diversity 29 [NZB] [BLK6] XXXXXXXXXXX XXXXXXXXXXXXXX XXXXXXXXXXXXXX AIYGYDGGYAMDY XXXXXXX XXXXXXX XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXX XXXXXXXXXXXXXXX XXXXXXXXXXXX XXXXXXXXXXXX XXXXXXXXXXXX XXXXXXXXXXXX XXXXXXXXXXXX XXXXXXXXXXXX XXXXXXXXXXXX
Slide 30: Biochemical characterization of anti-TIM-3 mAbs
30 Biochemical characterization of anti - TIM - 3 mAbs • Binding to rh - TIM - 3 - HIS by ELISA, and EC50 • Binding to cell - surface expressed TIM - 3 (HEK293 - TIM3+ cell line generated in house), and EC50 • Binding to human PBMCs • Binding to primate TIM - 3 protein and PBMCs • Epitope mapping •
Slide 31: Functional characterization of anti-TIM-3 mAbs
31 • Allo - MLR assay • Antigen recall assay (HIV or CMV) • Reversal of NK cell exhaustion (Melanoma) 31 Functional characterization of anti - TIM - 3 mAbs
Slide 32: TIM-3 program timelines
32 TIM - 3 program timelines • More screening to increase diversity (saturation) – End of July 2015 • Biochemical characterization – Q4 ‘15 • Functional characterization – Q4 ‘15 • Humanization – Q4 ‘15 – Q1 ‘16 32
Slide 33: Human TCR recovery
Human TCR recovery 33
Slide 34: Recovery of single T cells
34 Recovery of single T cells • Goal: use Enumeral platform to select specific T cells from patient samples and recover TCR gene sequences – Assess clonality of infiltrates – Assess repertoire changes/compare blood to disease microenvironment • Methods SOP development using Jurkat cells (following s
Slide 35: Overview of Davis Lab protocol
35 Overview of Davis Lab protocol 35
Slide 36: Successful retrieval of Va8.4Ja from Jurkat cells
36 Successful retrieval of V a 8.4J a 3 from Jurkat cells 36 isolate 1 isolate 2 isolate 3 amino acid alignment Ig blast against germline VDJ database CDR3 CDR3 CDR3
Slide 37: Successful retrieval of Vb12.3Jb1.2 from Jurkat cells
37 Successful retrieval of V b 12.3J b 1.2 from Jurkat cells 37 isolate 1 isolate 2 isolate 3 isolate 4 amino acid alignment CDR3 Ig blast against germline VDJ database CDR3 CDR3
Slide 38: Summary
38 Summary • Recovery of CDR3 sequences of TCR a and TCR b from single T cells successful • Methods development ongoing 38
Slide 39: THE POWER of HUMAN
THE POWER of HUMAN™
Enumeral Biomedical Holdings — Technical Presentation (July 2015) on 6ix